Cost‐effectiveness analysis of four glucagon‐like peptide‐1 or glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonists for the treatment of adult patients with overweight and obesity in China
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16581 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Wu Fu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Obesity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Health Commission of the People's Republic of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Aims
To evaluate the cost‐effectiveness of liraglutide, semaglutide, tirzepatide, benaglutide, and lifestyle management for the treatment of obesity from the perspective of the Chinese healthcare system. Materials and Methods This study gathered clinical trial data from literature reviews of each treatment strategy for patients with obesity without diabetes, and efficacy data were synthesized using network meta‐analysis. The data were subsequently incorporated into an constructed Markov model to simulate the lifetime treatment trajectory of patients, with a cycle length of one year. The model integrated epidemiological data from China, clinical efficacy, treatment costs, and utilities, calculating the total treatment costs and quality‐adjusted life years, followed by incremental cost‐effectiveness analysis. The willingness‐to‐pay (WTP) threshold was set at three times the per capita gross domestic product (GDP), amounting to $37 067.75. Sensitivity analysis and scenario analysis were performed.
Results
The incremental cost‐effectiveness ratios compared to lifestyle management for benaglutide, liraglutide, semaglutide, tirzepatide (10 mg), and tirzepatide (15 mg) were $227 355.26, $47 994.81, $42 818.20, $72 380.49, and $89 147.19. The base‐case results indicated that, under the WTP threshold, none of the four glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) or glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1RA therapies were cost‐effective compared with lifestyle management. In the probabilistic sensitivity analysis, under the WTP threshold, lifestyle management was the most likely to be cost‐effective. Scenario analysis showed that, in the severe obesity patient population and in first‐tier cities in China, semaglutide is the most cost‐effective treatment option.
Conclusions
GLP‐1 RA or GIP/GLP‐1RA are not cost‐effective for obesity treatment in China currently. Nevertheless, semaglutide exhibits relatively favourable economic potential across multiple subgroups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China.
- The School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, People's Republic of China.
- Department of Endocrinology, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China.
ORCID-Profile: Na Li
Förderung
- National Health Commission of the People's Republic of China
- National Natural Science Foundation of China
Zitieren
APA
Fu, W., Lin, J., You, C., Zhang, J., Lei, J., Zheng, L., Zheng, B., Liu, M., Liu, L., & Li, N. (2025). Cost‐effectiveness analysis of four glucagon‐like peptide‐1 or glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonists for the treatment of adult patients with overweight and obesity in China. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16581
Vancouver
Fu W, Lin J, You C, Zhang J, Lei J, Zheng L, et al. Cost‐effectiveness analysis of four glucagon‐like peptide‐1 or glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonists for the treatment of adult patients with overweight and obesity in China. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16581
BibTeX
@article{Fu2025,
author = {Fu, Wu and Lin, Jingwen and You, Caicong and Zhang, Jiahao and Lei, Jianying and Zheng, Liushi and Zheng, Bin and Liu, Maobai and Liu, Libin and Li, Na},
title = {Cost‐effectiveness analysis of four glucagon‐like peptide‐1 or glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonists for the treatment of adult patients with overweight and obesity in China},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16581}
}
EUVIMED